国际乳腺癌干预研究I(IBIS-I)中参与者报告的症状及其对长期依从性的影响
IBIS-I随机对照试验纳入英国样本中4,279名乳腺癌风险增高女性,随机分配他莫昔芬20 mg/天或安慰剂,分析3,823名女性。总体69.7%的女性依从至少4.5年(他莫昔芬65.2% vs 安慰剂74.0%,P<.001)。前6个月出现预设症状降低长期依从性,两治疗组效应相似,作者认为需干预支持症状管理。
要点
- 总体69.7%的女性依从至少4.5年,他莫昔芬组65.2% vs 安慰剂组74.0%(P<.001)。
- 恶心/呕吐与他莫昔芬组(OR 0.57)和安慰剂组(OR 0.58)依从性降低相关。
- 前6个月出现预设症状降低长期依从性,两治疗组效应相似,作者认为需干预支持症状管理。
核心结论
- 在IBIS-I试验中,前6个月内经历预设症状降低长期依从性,两治疗组效应相似,提示女性将年龄相关症状归因于预防治疗,作者认为需要干预以支持症状管理。
研究设计与样本
- IBIS-I为随机对照试验,研究他莫昔芬降低乳腺癌风险增高女性乳腺癌风险的有效性。
- 英国样本中女性随机分配至他莫昔芬20 mg/天或安慰剂(n=4,279),排除456例后,3,823名女性纳入分析。
- 依从性(<4.5年或≥4.5年)基于六次每月临床访视数据计算,分析校正年龄、Tyrer-Cuzick风险、吸烟、激素替代治疗使用、绝经状态、基线绝经症状和治疗。
主要发现
- 总体69.7%的女性依从至少4.5年(他莫昔芬组65.2% vs 安慰剂组74.0%,P<.001)。
- 治疗组间依从性差异从12个月起观察到(所有P<.01),在54个月时最大;脱落率在最初12至18个月最高,此后下降。
- 报告恶心/呕吐的女性在他莫昔芬组(OR 0.57,95%CI 0.37-0.86,P=.007)和安慰剂组(OR 0.58,95%CI 0.37-0.93,P=.023)依从性均较低。
- 头痛仅与安慰剂组依从性相关(OR 0.62,95%CI 0.42-0.91,P=.016),妇科症状仅在他莫昔芬组显著(OR 0.77,95%CI 0.62-0.97,P=.024);各症状对依从性的效应量在两治疗组间无显著差异(P>.05)。
- 两治疗组中,除头痛(P=.054)外,所有症状严重程度增加与依从性降低存在显著趋势(P<.01)。
临床怎么用
- 作者认为需要干预以支持症状管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To assess the role of participant-reported symptoms on long-term adherence to preventive therapy in the United Kingdom sample of the International Breast Cancer Intervention Study (IBIS-I). IBIS-I was a randomized controlled trial that investigated the effectiveness of tamoxifen in reducing the risk of breast cancer among women at increased risk of the disease. Participants and Methods Women were randomly assigned to tamoxifen versus placebo (20 mg/day; n = 4,279). After 456 exclusions, 3,823 women were included in this analysis. Adherence (< 4.5 years or ≥ 4.5 years) was calculated using data from six monthly clinical visits. Analyses were adjusted for age, Tyrer-Cuzick risk, smoking, use of hormone replacement therapy, menopausal status, baseline menopausal symptoms, and treatment. Results Overall, 69.7% of women were adherent for at least 4.5 years (tamoxifen: 65.2% v placebo: 74.0%; P < .001). Differences in adherence between treatment arms were observed from 12 months onward (all P < .01) and were largest at 54 months. Dropout rates were highest in the first 12 to 18 months and decreased thereafter. Women reporting nausea/vomiting were less likely to be adherent in both the tamoxifen (odds ratio [OR], 0.57; 95% CI, 0.37 to 0.86; P = .007) and placebo (OR, 0.58; 95% CI, 0.37 to 0.93; P = .023) arms. Headaches were associated with adherence only in the placebo arm (OR, 0.62; 95% CI, 0.42 to 0.91; P = .016), whereas gynecologic symptoms were significant only in the tamoxifen arm (OR, 0.77; 95% CI, 0.62 to 0.97; P = .024). Effect sizes for each symptom on adherence were not significantly different between the treatment groups ( P > .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms ( P < .01) except headaches ( P = .054). Conclusion In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.
引用
- Smith SG, Sestak I, Howell A, et al. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). J Clin Oncol. 2017. PMID: 28661758. doi:10.1200/JCO.2016.71.7439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。